SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : DNAP unlocking DNA coding
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Evan who started this subject5/17/2001 10:30:22 PM
From: Richard Chapman  Read Replies (1) of 95
 
For gleno a post of email he sent me.

Glen,

dailynews.yahoo.com

I can't remember if you were the one that sent me the
article on the buyout of Rosetta (RSTA) by Merck, but
here is my analysis after reading the article:

Although the article talks about the current troubles
that Genomic companies are having supporting
themselves by solely selling data, it is important to
differentiate between companies like Rosetta who
license their data directly to a handful of
pharmaceutical companies and DNAPrint who plans to
license their data directly to hospitals, doctor's
offices, etc. for use by their patents. These means
that while the potential customer base for Rosetta and
GeneLogic is maybe 50 pharmaceutical companies, the
potential customer base for DNAPrint's products in in
the hundreds of millions (or potentially every man,
woman, and child). That said, Merck still felt that
Rosetta was worth $620 million in the hopes that
Rosetta could help them find just one blockbuster
drug.

It is my feeling that DNAPrint's business model is far
superior to those of the other companies mentioned.
We realize that we are in a "race" to discover this
information since the first companies to discover
these associations control the patents and thus their
future use (equating to huge profits down the road).
It is estimated that the market for personalized
medicine products will be in excess of $100 billion
and we expect to be the premier player in that market.

DNAPrint is not looking to be bought out. It is the
company's intention to continue to grow organically as
it makes discoveries and increases its database of
intellectual property. However, since we are a public
company it is our fiduciary responsibility to evaluate
any and all buy-out offers.

DNAPrint was created because our founders believed
that there was a better way to practice medicine.
DNAPrint plans on making "personalized medicine" a
reality. If we are correct, then everyone will
benefit.

Regards,
Craig Hall
Investor Relations
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News